Nyxoah S.A. (NYXH) Stock

Nyxoah S.A. (NYXH) is a Healthcare stock trading at $1.61 (as of 2026-06-18), with a market capitalization of $127.36M and a trailing P/E of -1.3. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Nyxoah S.A. develops and commercializes medical solutions for sleep-disordered breathing, including the Genio system for hypoglossal neurostimulation to treat moderate to severe obstructive sleep apnea. The company is headquartered in Mont-Saint-Guibert, Belgium, and serves patients who require therapy for obstructive sleep apnea.

Valuation — source: SEC EDGAR (first-party)
Price$1.61
Market Cap$127.36M
P/E Ratio-1.3
Price / Book2.59
DCF Value (model)$-27.11
DCF Upside vs Price-1778.6%
Profitability & Growth — source: SEC EDGAR
Return on Equity-183.4%
Current Ratio1.25
Valuation vs Sector & Industry
Stock P/E-1.3
Sector P/E (Healthcare)21.0
Industry P/E (Medical Equipment)31.7
vs Sector-106.0%
vs Industry-103.9%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVestal Point Capital, LP ($2.54M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryMedical Equipment
CEOOlivier Taelman
Employees183
CountryBE
IPO Date2021-04-28

Related Companies (Business model: Medical Devices / Life Science Tools; 8 closest by market cap; US-domiciled)

  • Quantum-Si incorporated (QSI)
  • Sanara MedTech Inc. (SMTI)
  • Stereotaxis, Inc. (STXS)
  • Anteris Technologies Global Corp. (AVR)
  • Nano-X Imaging Ltd. (NNOX)
  • 908 Devices Inc. (MASS)
  • CVRx, Inc. (CVRX)
  • Electromed, Inc. (ELMD)
NYXH earnings history · NYXH institutional & insider holders · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-06-18.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.